Contents
[hide]
[show]

Optic atrophy type 1, or autosomal dominant optic atrophy (ADOA), is a rare genetic condition characterized by the degeneration of the optic nerves. This condition affects the energy-producing centers within the cells of the optic nerves, leading to vision loss and damage to the central vision.

Research has shown that optic atrophy type 1 is typically inherited in an autosomal dominant pattern, which means that a disease-causing mutation in one copy of the gene is enough to cause the condition. The most common gene associated with this condition is called OPA1.

Patients with optic atrophy type 1 usually experience a gradual loss of vision, which may begin in early childhood or later in life. Additional symptoms may include visual disturbances, such as blurred or distorted vision, and difficulty distinguishing colors.

Diagnosis of optic atrophy type 1 can be made through genetic testing, which can identify mutations in the OPA1 gene. It is important to note that genetic testing may not identify all cases, as there may be other genes involved in the development of this condition.

Treatment for optic atrophy type 1 is focused on managing the symptoms and providing support to patients. Currently, there is no cure for this condition. However, there are various resources and organizations that offer support and information for patients and their families, including advocacy groups and clinical trials.

Further research is needed to understand the underlying mechanisms of optic atrophy type 1 and to develop potential treatments. Studies investigating the role of mitochondrial maintenance and energy phosphorylation in the optic nerves may provide additional insights into the causes of this condition.

As of August 2020, the most expensive drug in America is Myalept, a drug used to treat leptin deficiency. A month’s worse of this drug costs $71, 306 per month, according to research from GoodRx. Myalept is known as an “orphan drug” because it’s intended to treat a rare disease.

In conclusion, optic atrophy type 1 is a rare genetic condition that leads to the degeneration of the optic nerves and vision loss. Genetic testing can help diagnose this condition, although not all cases may be identified through current testing methods. It is important for patients and healthcare providers to stay updated on the latest scientific and clinical trial research to learn more about this condition and explore potential treatment options.

Frequency

Optic atrophy type 1, also known as autosomal dominant optic atrophy (ADOA) or Kjer type optic atrophy, is a rare hereditary genetic condition characterized by the degeneration of the optic nerves.

The frequency of optic atrophy type 1 is estimated to be around 1 in 12,000 individuals. It is one of the most common genetic optic nerve diseases and accounts for a significant proportion of hereditary optic atrophy cases.

The condition is caused by mutations in the OPA1 gene, which is responsible for the maintenance of mitochondrial function and energy production in cells. Mutations in this gene can lead to impaired mitochondrial function and reduced energy production in the optic nerves, resulting in their degeneration.

ClinicalTrials.gov, a database of clinical studies, lists several studies related to optic atrophy type 1. These studies aim to further understand the disease, identify additional associated genes, and explore potential treatment options. Scientific articles and resources about the condition can also be found in databases like PubMed and OMIM.

Many organizations and advocacy groups provide support and resources for individuals and families affected by optic atrophy type 1. These resources can include information about the condition, genetic testing, clinical trials, and more.

Overall, optic atrophy type 1 is a rare genetic condition that affects the optic nerves and visual function. Further research and clinical studies are needed to learn more about the frequency, causes, and treatment options for this condition.

Causes

Optic atrophy type 1 (ADOA) is a rare genetic condition characterized by the degeneration of the optic nerves. It is usually inherited in an autosomal dominant manner, meaning that individuals have a 50% chance of inheriting the condition from an affected parent.

The most common genetic cause of ADOA is a mutation in the OPA1 gene. This gene provides instructions for making a protein involved in the maintenance and organization of mitochondria, the energy-producing structures within cells. Mutations in the OPA1 gene disrupt the normal function of mitochondria in the optic nerves, leading to their degeneration.

Research on ADOA has also identified other genes associated with the condition, such as OPA3 and OPA4. These genes may play a role in the phosphorylation of OPA1 and further contribute to the degeneration of the optic nerves.

ADOA is associated with a range of visual symptoms, including decreased visual acuity, color vision abnormalities, and visual field defects. The severity and frequency of these symptoms can vary among individuals with ADOA.

In addition to genetic causes, there are other rare conditions and diseases that can cause optic atrophy. These may include mitochondrial diseases, Leber hereditary optic neuropathy (LHON), and Kjer-type optic atrophy. Further research is needed to fully understand the causes and mechanisms of these conditions.

Scientific studies and research articles on optic atrophy and related genetic diseases can be found in resources such as PubMed, OMIM, and clinicaltrials.gov. These sources provide valuable information on the genetics, inheritance patterns, and clinical characteristics of optic atrophy type 1.

For more information on ADOA, its causes, and support resources, individuals can visit the Optic Atrophy Information Center and advocacy organizations dedicated to raising awareness and supporting patients with ADOA.

Learn more about the gene associated with Optic atrophy type 1

The gene associated with Optic atrophy type 1 is called OPA1. OPA1 is located on the long arm of chromosome 3 (3q28-q29), and it encodes a protein that is involved in the maintenance and regulation of mitochondria, which are responsible for energy production within cells.

Optic atrophy type 1 (OA1) is a rare genetic condition characterized by degeneration of the optic nerves. It is also known as Autosomal Dominant Optic Atrophy (ADOA) or Kjer’s hereditary optic atrophy. This condition primarily affects the optic nerves, which transmit visual information from the eyes to the brain.

Mutations in the OPA1 gene lead to the production of a dysfunctional protein, which affects the structure and function of mitochondria in the optic nerves. This disruption of mitochondrial function eventually leads to the degeneration of these nerves, causing vision loss.

Patients with Optic atrophy type 1 usually begin to experience vision problems in childhood or adolescence. The severity and progression of the condition can vary greatly between individuals, even within the same family.

See also  AMACR gene

Research on the OPA1 gene and Optic atrophy type 1 is ongoing, and there are several scientific organizations and resources that provide additional information and support for patients and their families. Some of these resources include:

  • Pubmed: A database of scientific publications that provides access to research studies on Optic atrophy type 1 and the OPA1 gene.
  • OMIM: Online Mendelian Inheritance in Man (OMIM) is a comprehensive catalog of genetic diseases and their associated genes. It provides detailed information on the genetic causes, clinical features, and inheritance patterns of Optic atrophy type 1.
  • ClinicalTrials.gov: This is a registry of clinical trials conducted around the world. It includes information on ongoing and completed studies related to Optic atrophy type 1, including research on new treatments or therapies.

Further studies and research are necessary to fully understand the role of the OPA1 gene and its associated protein in the development and maintenance of optic nerves. Additional research may also provide further support for the use of phosphorylation and other genetic testing methods in diagnosing and managing Optic atrophy type 1.

For more information about Optic atrophy type 1 and the OPA1 gene, please refer to the citations and references provided.

Inheritance

Optic atrophy type 1 is a rare genetic condition that is inherited in an autosomal dominant manner. This means that an affected individual has a 50% chance of passing the condition on to each of their children. The condition is caused by mutations in the OPA1 gene, which provides instructions for making a protein involved in the maintenance and energy production within mitochondria, the energy-producing structures in cells.

There are more than 200 known mutations in the OPA1 gene that can cause optic atrophy type 1. These mutations lead to a deficiency in mitochondrial phosphorylation and result in the degeneration of the optic nerves, leading to vision loss. There are several other genes that have been associated with optic atrophy, but OPA1 is the most common gene associated with optic atrophy type 1.

Genetic testing can be used to confirm a diagnosis of optic atrophy type 1. This testing can identify specific mutations in the OPA1 gene and help determine the inheritance pattern within a family. It is important for individuals with optic atrophy type 1 and their family members to undergo genetic testing to better understand the condition and its potential impact on future generations.

For more information about optic atrophy type 1 and genetic testing, resources such as the National Organization for Rare Disorders (NORD), OMIM (Online Mendelian Inheritance in Man), and PubMed can provide further support and references to scientific articles and clinical trials related to the condition. Additionally, organizations such as the Kjer Research and Support Center and the Optic Nerve Atrophy Patient Registry and Information Center offer valuable information and resources for individuals with optic atrophy and their families.

Other Names for This Condition

Optic atrophy type 1, also known as Autosomal Dominant Optic Atrophy (ADOA), is a rare genetic disorder that affects the optic nerves. It is characterized by progressive degeneration and loss of nerve cells in the retina, which leads to vision impairment and can result in legal blindness.

Several other names are used to refer to this condition, including:

  • Hereditary optic atrophy
  • Kjer optic atrophy

These names are derived from the researchers who first described the condition and the associated clinical features. The Kjer Optic Atrophy Research Center is one of the leading organizations dedicated to studying this condition, and they conduct research studies and clinical trials to further understand its causes, inheritance patterns, and potential treatment options.

Information about the condition, including its frequency, genetic causes, and clinical presentations, can be found in scientific articles and resources such as PubMed, OMIM, and ClinicalTrials.gov. These resources provide valuable information for healthcare professionals, researchers, and patients seeking to learn more about Optic Atrophy Type 1.

Genetic testing is often recommended for individuals suspected of having Optic Atrophy Type 1 to confirm the diagnosis and identify the specific genetic mutation. This information can help guide treatment decisions and provide information about the inheritance pattern within a family.

Support and advocacy organizations, such as the Optic Atrophy Support Group and the United Mitochondrial Disease Foundation, also offer resources and support for individuals and families affected by this condition. They provide information about available support services, research updates, and opportunities to connect with others who are going through similar experiences.

In addition to Optic Atrophy Type 1, there are other forms of optic atrophy that can have similar clinical features but are associated with different genes and inheritance patterns. It is important to consider these other conditions in the differential diagnosis and explore further testing if necessary.

References and additional resources:

  • ClinicalTrials.gov: A catalog of clinical trials for Optic Atrophy Type 1 and related diseases
  • PubMed: A database of scientific articles on Optic Atrophy Type 1 and related diseases
  • OMIM: A comprehensive catalog of human genes and genetic disorders, including Optic Atrophy Type 1
  • Optic Atrophy Support Group: An organization that provides support and resources for individuals and families affected by Optic Atrophy Type 1
  • United Mitochondrial Disease Foundation: An advocacy organization for individuals and families affected by mitochondrial diseases, including Optic Atrophy Type 1

Further research and scientific studies are crucial to better understand the underlying mechanisms, develop targeted treatments, and improve the overall management and quality of life for patients with Optic Atrophy Type 1.

Additional Information Resources

  • Adoa.org: The Adoa.org website provides information and resources for individuals and families affected by optic atrophy type 1 (ADOA) and other related genetic diseases.
  • OMIM: The Online Mendelian Inheritance in Man (OMIM) database offers detailed information about the genetic causes of optic atrophy type 1 and other associated conditions. It includes gene names, inheritance patterns, and clinical features.
  • PubMed: PubMed is a database of scientific articles from various research studies and clinical trials. It offers additional information on optic atrophy type 1, including studies on the genetic causes, clinical presentation, and management of the condition.
  • Neurol-Genetics: This research organization specializes in the study of neurological genetic diseases, including optic atrophy type 1. Their website provides resources and information for patients and healthcare professionals.
  • Kjer’s Optic Atrophy Resources: Kjer’s Optic Atrophy Resources is a comprehensive catalog of information and support for individuals and families affected by optic atrophy. It includes articles, patient support organizations, and genetic testing resources.
  • ClinicalTrials.gov: ClinicalTrials.gov is a database of clinical trials taking place around the world. It provides information about ongoing or completed studies related to optic atrophy type 1 and other rare genetic diseases.

Genetic Testing Information

Optic atrophy type 1 (OPA1) is a rare genetic condition that affects the optic nerves and usually causes progressive vision loss. Genetic testing can be used to confirm a diagnosis of OPA1 and to determine the specific genetic mutation involved.

See also  HADHB gene

There are several genes associated with OPA1, including the OPA1 gene. Mutations in these genes can result in the characteristic symptoms of optic atrophy. Genetic testing can identify these mutations and help healthcare providers better understand the condition and its inheritance patterns.

Genetic testing for OPA1 can be done through various methods, such as DNA sequencing and gene panel testing. These tests analyze the patient’s DNA to identify any mutations or variants in the genes associated with OPA1. This information can be used for diagnostic purposes and to provide information about the prognosis and management of the condition.

Genetic testing for OPA1 can be beneficial for patients and their families in several ways:

  • Confirming a diagnosis of OPA1
  • Providing information about the inheritance pattern of the condition
  • Assisting in family planning decisions
  • Guiding treatment and management options
  • Identifying potential at-risk family members

It’s important to note that OPA1 is a rare genetic condition, so genetic testing may not be readily available or covered by insurance. Patients and their families can reach out to advocacy organizations and support groups for more information and resources on genetic testing for OPA1.

Genetic testing for OPA1 can be conducted at specialized centers or laboratories that offer genetic testing services. These centers may have additional information and resources about OPA1 and other related genetic diseases.

Further information about OPA1 and genetic testing can be found in scientific articles and databases such as OMIM, PubMed, and the Online Mendelian Inheritance in Man (OMIM) catalog. These resources provide detailed information about the genetics of optic atrophy and other related conditions.

ClinicalTrials.gov is also a valuable resource for information on ongoing research studies and clinical trials related to OPA1 and optic atrophy. These studies may provide further insights into the genetics and treatment options for the condition.

In conclusion, genetic testing can provide important information about the diagnosis, inheritance, and management of optic atrophy type 1. Patients and their families can seek support from advocacy organizations, healthcare providers, and specialized genetic testing centers to learn more about genetic testing options and resources available.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is an organization that provides reliable information about genetic and rare diseases. GARD is a program of the National Center for Advancing Translational Sciences (NCATS) and is funded by the National Institutes of Health (NIH).

GARD is a valuable resource for individuals who are affected by or interested in learning more about genetic and rare diseases. The center provides information about various types of diseases, including Optic Atrophy Type 1.

Optic Atrophy Type 1 is a rare condition that affects the optic nerves, which are responsible for transmitting visual information from the eyes to the brain. It is also known as Autosomal Dominant Optic Atrophy (ADOA) and Kjer Disease.

This condition is usually inherited in an autosomal dominant manner, meaning that a person only needs to inherit one copy of the mutated gene from one parent in order to develop the condition. Mutations in the OPA1 gene are associated with Optic Atrophy Type 1.

Common symptoms of Optic Atrophy Type 1 include vision loss, difficulties with color vision, and a pale appearance of the optic nerves. The severity and progression of the condition can vary from person to person.

There is currently no cure for Optic Atrophy Type 1. Treatment aims to manage the symptoms and support the visual and neurological functions. Supportive measures may include low vision aids, occupational therapy, and genetic counseling for affected individuals and their families.

Research studies and clinical trials are underway to better understand Optic Atrophy Type 1 and explore potential treatments. These studies may also provide opportunities for affected individuals to participate in research and clinical trials.

For more information about Optic Atrophy Type 1 and other related diseases, you can visit the GARD website and search for “Optic Atrophy Type 1” or the specific scientific names you may find in scientific publications and research articles.

Additional resources for information and support include PubMed, OMIM (Online Mendelian Inheritance in Man), and ClinicalTrials.gov. These resources provide access to scientific publications, genetic testing information, and ongoing clinical trials related to Optic Atrophy Type 1 and other rare diseases.

References:

  • Genetic and Rare Diseases Information Center (GARD)
  • National Center for Advancing Translational Sciences (NCATS)
  • National Institutes of Health (NIH)
  • PubMed database
  • Online Mendelian Inheritance in Man (OMIM)
  • ClinicalTrials.gov

For further information about Optic Atrophy Type 1, associated genes, inheritance patterns, and more, you can also reach out to patient advocacy organizations that focus on rare diseases and optic atrophy. These organizations can provide support, resources, and additional information.

Patient Support and Advocacy Resources

Patients with Optic Atrophy Type 1 and their families can find support and advocacy resources to help them navigate this condition. These resources provide more information about the genes associated with optic atrophy, inheritance patterns, and available treatments.

  • Research articles and scientific references: Patients and their families can learn more about optic atrophy from scientific articles and references. PubMed and ClinicalTrials.gov are reliable sources for finding scientific articles on optic atrophy and related conditions.
  • Patient support organizations: Various patient support organizations provide information, resources, and support for patients with optic atrophy. These organizations often have the latest updates on research and treatment options. The Kjer’s Optic Neuropathy Support and Advocacy Center is an example of such an organization.
  • Genetic testing and counseling: Genetic testing can help determine the specific gene associated with optic atrophy and provide information about inheritance patterns. Patients and their families can consult with genetic counselors to learn more about their specific genetic condition and the associated risks.
  • OMIM and GeneReviews: The Online Mendelian Inheritance in Man (OMIM) database and GeneReviews provide comprehensive information on various genetic diseases, including optic atrophy. These resources include clinical descriptions, associated genes, inheritance patterns, and management guidelines.
  • Additional resources: For rare genetic conditions like optic atrophy, it may be helpful to explore other resources such as patient forums, social media groups, and online communities where individuals with similar conditions can share experiences and support one another.

By accessing these resources, patients and their families can gain a better understanding of their condition, learn about available treatments, and connect with others facing similar challenges. It is important to stay informed and engaged in research and advocacy efforts to support further studies and advancements in the field of optic atrophy.

Research Studies from ClinicalTrials.gov

The catalog of research studies from ClinicalTrials.gov provides valuable information on rare diseases, such as Optic Atrophy Type 1. These studies help in understanding the genetic basis of this condition and support the development of effective treatments.

See also  KRT1 gene

Optic Atrophy Type 1 is a rare hereditary optic neuropathy that affects the optic nerves within the brain. It is often associated with mutations in several genes, including OPA1 and OPA3. This condition causes the progressive degeneration and loss of the optic nerves, resulting in visual impairment.

Research studies from ClinicalTrials.gov provide insights into the genetic basis of Optic Atrophy Type 1. They explore the frequency of mutations in these genes and their association with mitochondrial inheritance. These studies also investigate the role of phosphorylation in the maintenance of energy within the optic nerves.

Patients with Optic Atrophy Type 1 can find additional support and resources through advocacy and research centers. These centers provide genetic information, scientific articles, and clinical trial references related to Optic Atrophy Type 1. OMIM and PubMed are also valuable resources for gathering information about this rare condition.

Further research studies from ClinicalTrials.gov are being conducted to better understand Optic Atrophy Type 1 and develop effective treatments. These studies explore the use of gene therapy, neuroprotective agents, and other treatment modalities to improve visual outcomes for patients with this condition.

The Kjer Sequence (also known as Kjer Inheritance) is a specific genetic association found in some individuals with Optic Atrophy Type 1. Further studies are needed to understand the genetic mechanisms underlying this association and its implications for disease progression and treatment.

In summary, research studies from ClinicalTrials.gov provide valuable insights into Optic Atrophy Type 1 and other rare optic neuropathies. These studies help in understanding the genetic basis, associated diseases, and maintenance of energy within the optic nerves. Further research is needed to develop effective treatments and improve outcomes for patients with this condition.

Catalog of Genes and Diseases from OMIM

OMIM (Online Mendelian Inheritance in Man) is a comprehensive catalog of genes and rare hereditary diseases. It provides information about the genes associated with various genetic conditions, including Optic Atrophy Type 1 (ADOA).

ADOA is a rare genetic condition that usually affects the optic nerves, leading to vision loss. It is associated with mutations in the OPA1 gene, which plays a crucial role in mitochondrial function and energy production within cells.

The inheritance of ADOA is usually autosomal dominant, meaning that a mutation in one copy of the OPA1 gene is enough to cause the condition. However, in some cases, autosomal recessive inheritance has been reported.

Patient resources, such as support groups and advocacy organizations, can provide additional information and support for individuals and families affected by ADOA. These organizations may also offer resources for genetic testing, clinical trials, and research studies on the condition.

Further research is needed to understand the exact mechanisms by which OPA1 gene mutations cause optic atrophy and associated visual impairment. Some studies suggest that abnormal mitochondrial function, energy production, and impaired phosphorylation may play a role.

OMIM provides a catalog of genes associated with ADOA and other optic atrophy-related diseases. The catalog includes the genetic names of the associated genes, the clinical features of the diseases, and references to relevant articles and research studies, including those published in PubMed.

To learn more about genes and diseases associated with ADOA, you can visit the OMIM website. OMIM is a valuable resource for healthcare professionals, researchers, and individuals interested in rare genetic diseases.

Resources

Scientific Articles on PubMed

Optic atrophy type 1 (ADOA) is a hereditary condition associated with autosomal dominant inheritance. It is characterized by the degeneration of optic nerves, resulting in visual impairment. ADOA is usually caused by mutations in the OPA1 gene, which is responsible for the maintenance of mitochondrial function and energy production within the optic nerves.

PubMed, a database of scientific articles, provides a wealth of information on optic atrophy type 1. Here are some key resources and references to explore:

  • OMIM (Online Mendelian Inheritance in Man) – this organization catalogues information on genetic diseases, including ADOA. Their website provides detailed information on the genetic causes, inheritance patterns, and clinical features of ADOA. Visit OMIM.
  • Pubmed – PubMed contains a vast collection of scientific articles on ADOA. By searching for keywords such as “optic atrophy type 1” or “ADOA”, you can find research papers, clinical studies, and other scientific resources related to the condition. Search on PubMed.
  • ClinicalTrials.gov – This website provides information on ongoing clinical trials and studies related to ADOA. It is an excellent resource for patients, caregivers, and healthcare professionals interested in participating in or learning about clinical research on this condition. Explore ClinicalTrials.gov.

In addition to these resources, you may also find the following articles helpful in understanding optic atrophy type 1:

  • Kjer’s hereditary optic atrophy: a 25-year follow-up. This article discusses the clinical features, inheritance patterns, and long-term prognosis of Kjer’s hereditary optic atrophy, a rare form of ADOA. It highlights the importance of genetic testing and provides insight into the management and support of patients with this condition. Read the article.
  • Phosphorylation of OPA1 by MAPKAPK2 Links Mitochondrial Fusion to Environmental Stress. This scientific paper explores the role of OPA1 phosphorylation, a process involving the modification of the OPA1 protein, in the regulation of mitochondrial fusion and energy production. It provides valuable insights into the cellular mechanisms underlying mitochondrial dysfunction in ADOA. Read the article.
  • Rare mitofusin 2 variant associations in autosomal recessive Charcot-Marie-Tooth disease. Mitofusin 2 (MFN2) is a gene associated with optic atrophy type 1 and other neurological disorders. This study investigates the frequency and clinical characteristics of MFN2 variants and their associations with rare forms of Charcot-Marie-Tooth disease, providing further understanding of the genetic basis and disease spectrum of ADOA. Read the article.

These scientific articles, along with the resources mentioned, provide valuable information on optic atrophy type 1 and its genetic and clinical aspects. They contribute to ongoing research and help advance our understanding of this rare condition.

References

  • Kjer, P., 1983. Low incidence of hearing loss in 35 Danish patients with autosomal dominant optic atrophy. Neurology, 33(11), pp.1586-1588.
  • Votruba, M., 2004. Molecular genetic basis of primary inherited optic neuropathies. Eye, 18(11), pp.1126-1132.
  • Optic Atrophy 1, Autosomal Dominant; OPA1. (2019) Retrieved from: https://www.omim.org/entry/165500
  • Fereira, C., et al. (2015). OPA1-related disorders: Diversity of clinical expression, modes of inheritance and pathophysiology. Neurobiol.Dis., 90, pp.20-26.
  • Optic Atrophy 1; OPA1. (2019) Retrieved from: https://pharaoh.igh.cnrs.fr/m.php?p=home&c=GENE&a=OPA1
  • Rendon, A., et al. (2020). Optic Atrophy 1 (OPA1) and disorders of mitochondrial dynamics. Molecular Syndromology, 10(3), pp.115-130.
  • ClinicalTrials.gov. (2019). OPA1 Mutations In ADOPEN1 (OPA1 Mutations). Retrieved from: https://clinicaltrials.gov/ct2/show/NCT02064569
  • Genetics Home Reference. (2019). OPA1 gene. Retrieved from: https://ghr.nlm.nih.gov/gene/OPA1#resources
  • Disease Information and Resources. (2019). Optic Atrophy Type 1 (OPA1). Retrieved from: https://www.mitoaction.org/mito-resource/optic-atrophy-type-1-opa1

Related Posts